Ashley Newcomb
A5039582877- Intraperitoneal and Appendiceal Malignancies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Vaccine Coverage and Hesitancy
- RNA modifications and cancer
- Psychology of Development and Education
- Genetic factors in colorectal cancer
- Grief, Bereavement, and Mental Health
- Trauma and Emergency Care Studies
- Youth Development and Social Support
- Opioid Use Disorder Treatment
- Lung Cancer Treatments and Mutations
- E-Learning and COVID-19
- Homicide, Infanticide, and Child Abuse
- Renal cell carcinoma treatment
Dana-Farber Cancer Institute
2022-2024
Harvard University
2024
NYU Langone Health
2020
New York University
2020
Wentworth Douglass Hospital
2019
Background Breast cancer is the leading cause of female mortality in low-income and middle-income countries (LMICs). Early detection breast cancer, either through screening or early diagnosis initiatives, led by community health workers (CHWs) has been proposed as a potential way to address unjustly high rates. We therefore document: (1) where how CHWs are currently deployed this role; (2) trained, including content, duration outcomes training; (3) evidence on costs associated with deploying...
PURPOSE Until human papillomavirus (HPV)–based cervical screening is more affordable and widely available, visual inspection with acetic acid (VIA) recommended by the WHO for in lower-resource settings. Visual will still be required to assess cervix women whose positive high-risk HPV. However, quality of VIA can vary widely, it difficult maintain a well-trained cadre providers. We developed smartphone-enhanced platform (SEVIA) real-time secure sharing images remote supportive supervision,...
Observational clinicogenomic data sets, consisting of tumor next-generation sequencing (NGS) linked to clinical records, are commonly used for cancer research. However, in real-world practice, oncologists frequently request NGS search treatment options progressive cancer. The extent and impact this dynamic on analysis research not well understood.
Abstract Patients with non-small cell lung cancer (NSCLC) who have distant metastases a poor prognosis. To determine which genomic factors of the primary tumor are associated metastasis, we analyzed data from 759 patients originally diagnosed stage I–III NSCLC as part AACR Project GENIE Biopharma Collaborative consortium. We found that TP53 mutations were significantly development new metastases. also more prevalent in history smoking, suggesting these may be at increased risk for...
Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical molecular perspective using the American Association of Cancer Research Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC) registry. Patients' tumor samples underwent targeted next-generation sequencing. Clinical characteristics treatment outcomes were collected retrospectively. Overall survival (OS) advanced...
<div>Abstract<p>Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical molecular perspective using the American Association of Cancer Research Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC) registry. Patients’ tumor samples underwent targeted next-generation sequencing. Clinical characteristics treatment outcomes were collected retrospectively. Overall...
<div>Abstract<p>Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical molecular perspective using the American Association of Cancer Research Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC) registry. Patients’ tumor samples underwent targeted next-generation sequencing. Clinical characteristics treatment outcomes were collected retrospectively. Overall...
<p>OS from diagnosis of advanced disease (<b>A,</b> PM vs. non-PM; <b>B,</b> only and other sites <b>C,</b> stage IV: <b>D,</b> I–III with later development distant metastasis: non-PM).</p>
<p>Flowchart of patient selection from GENIE BPC colorectal cancer registry.</p>
<p>Definitions of patient-level MSI and MMR statuses</p>
<p>Oncoprint of patients with peritoneal metastasis</p>
<p>Supplementary Figure 2. Oncoprint from patients without peritoneal metastasis</p>
<p>Univariable and multivariable Cox proportional hazards models for OS</p>
<p>Supplementary Figure 2. Oncoprint from patients without peritoneal metastasis</p>
<p>Frequencies of genomic alterations in tumor samples—Results are displayed for present at least 7% specimens and tested 20% the specimens, as well <i>NRAS</i> <i>MED12.</i> Frequencies do not reflect OncoKB annotation. Details specific NGS panels performed can be found GENIE data guide (<a href="www.aacr.org/wp-content/uploads/2022/02/GENIE_data_guide_11.0-public-1.pdf"...
<p>Univariable and multivariable logistic regression models for associations between baseline characteristics the presence of PM</p>
<p>PFS from initiation of first-line cancer-directed regimen (<b>A,</b> PM vs. non-PM; <b>B,</b> only and other sites <b>C,</b> stage IV: <b>D,</b> I–III with later development distant metastasis: non-PM).</p>
<p>Flowchart of patient selection from GENIE BPC colorectal cancer registry.</p>
<p>Clinical and pathologic characteristics of the study cohort</p>
<p>OS from diagnosis of advanced disease (<b>A,</b> PM vs. non-PM; <b>B,</b> only and other sites <b>C,</b> stage IV: <b>D,</b> I–III with later development distant metastasis: non-PM).</p>
<p>Oncoprint of patients with peritoneal metastasis</p>
<p>Clinical and pathologic characteristics of the study cohort</p>
<p>Definitions of patient-level MSI and MMR statuses</p>